Cempra Inc (NASDAQ:CEMP) has been assigned an average recommendation of “Hold” from the twenty brokerages that are covering the firm. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $8.52.
Several equities research analysts have recently commented on the stock. Vetr cut shares of Cempra from a “hold” rating to a “sell” rating and set a $4.07 price target for the company. in a research report on Monday. Ladenburg Thalmann Financial Services cut shares of Cempra from a “buy” rating to a “neutral” rating in a research report on Thursday, December 29th. Jefferies Group LLC reiterated an “underperform” rating and set a $2.00 price target on shares of Cempra in a research report on Wednesday, March 1st. Stifel Nicolaus reiterated a “hold” rating and set a $4.00 price target on shares of Cempra in a research report on Wednesday, March 1st. Finally, Cowen and Company reiterated a “hold” rating on shares of Cempra in a research report on Monday, January 2nd.
ILLEGAL ACTIVITY WARNING: “Analysts Set Cempra Inc (CEMP) Target Price at $8.52” was first posted by Mideast Time and is the property of of Mideast Time. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.mideasttime.com/analysts-set-cempra-inc-cemp-target-price-at-8-52/1590202.html.
In related news, Director Dov A. Md Goldstein sold 150,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 8th. The shares were sold at an average price of $3.55, for a total transaction of $532,500.00. Following the completion of the transaction, the director now owns 95 shares in the company, valued at $337.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Dov A. Md Goldstein sold 105,460 shares of the business’s stock in a transaction that occurred on Friday, January 13th. The shares were sold at an average price of $3.40, for a total transaction of $358,564.00. Following the transaction, the director now owns 95 shares of the company’s stock, valued at approximately $323. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,193,060 shares of company stock valued at $4,088,280. Corporate insiders own 17.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of CEMP. BlackRock Investment Management LLC boosted its position in shares of Cempra by 8.9% in the third quarter. BlackRock Investment Management LLC now owns 167,412 shares of the company’s stock worth $4,051,000 after buying an additional 13,631 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Cempra by 43.5% in the third quarter. JPMorgan Chase & Co. now owns 398,622 shares of the company’s stock worth $9,647,000 after buying an additional 120,747 shares in the last quarter. M&T Bank Corp purchased a new position in shares of Cempra during the third quarter worth about $449,000. KBC Group NV purchased a new position in shares of Cempra during the third quarter worth about $3,039,000. Finally, CAM Group Holding A S boosted its position in shares of Cempra by 22.7% in the third quarter. CAM Group Holding A S now owns 896,800 shares of the company’s stock worth $21,703,000 after buying an additional 166,170 shares in the last quarter. Hedge funds and other institutional investors own 79.92% of the company’s stock.
Shares of Cempra (NASDAQ:CEMP) opened at 4.35 on Tuesday. The stock’s market cap is $227.91 million. The firm has a 50-day moving average of $3.58 and a 200-day moving average of $9.85. Cempra has a 52-week low of $2.55 and a 52-week high of $26.95.
Cempra (NASDAQ:CEMP) last issued its quarterly earnings results on Tuesday, February 28th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.03. Cempra had a negative return on equity of 59.94% and a negative net margin of 678.72%. The business had revenue of $7.95 million for the quarter, compared to analyst estimates of $4.19 million. During the same quarter in the prior year, the firm earned ($0.48) EPS. The firm’s quarterly revenue was up 37.3% compared to the same quarter last year. On average, equities analysts expect that Cempra will post ($1.17) EPS for the current fiscal year.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.
Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with MarketBeat.com's FREE daily email newsletter.